Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

25.10.2017 | short review

Antiangiogenic therapies in colorectal cancer

verfasst von: Elisabeth Stragier, Hans Prenen, MD, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Summary

Angiogenesis is a very important step in the development of cancer. Several antiangiogenic biological agents have been studied during the past two decades for the treatment of colorectal cancer, both in adjuvant and metastatic settings. The first and most intensively studied is bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor. Since its approval in 2004, other antiangiogenic agents have been evaluated in clinical trials and some subsequently approved for the treatment of metastatic colorectal cancer such as aflibercept, ramucirumab, and regorafenib. In general, antiangiogenic agents show a modest efficacy in patients with metastatic colorectal cancer but not in the adjuvant setting. Also, there are no predictive biomarkers that could aid in selecting responsive patients. In this review we summarize the results of the completed large clinical trials investigating the efficacy of antiangiogenic therapies in colorectal cancer.
Vorheriger Artikel Novel concepts of antiangiogenic therapies in metastatic renal cell cancer
Nächster Artikel ASCO update on lymphoma
Literatur
1.
Ryerson AB, Eheman CR, Altekruse SF, et al. Annual report to the nation on the status of cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122:1312–37.CrossRefPubMedPubMedCentral
2.
Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst. 2011;103:21–30.CrossRefPubMed
3.
4.
Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: Animal models of the angiogenic switch. Cell Cycle. 2006;5:1779–87.CrossRefPubMed
5.
Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol. 2004;22:3395–407.CrossRefPubMed
6.
André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.CrossRefPubMed
7.
Allegra CJ, Yothers G, O’Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon : results of NBSAP protocol C‑08. J Clin Oncol. 2011;29:11–6.CrossRefPubMed
8.
de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): A phase 3 randomized controlled trial. Lancet Oncol. 2012;13:1225–33.CrossRefPubMed
9.
Kerr RS, Love E, Johnstone E, et al. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): An open-label, randomized phase 3 trial. Lancet Oncol. 2016;17:1543–57.CrossRefPubMed
10.
Pogue-Geile K, Yothers G, Taniyama Y, et al. Defective mismatch repair and benefit from bevacizumab for colon cancer: Findings from NSABP C‑08. J Natl Cancer Inst. 2013;105:989–92.CrossRefPubMedPubMedCentral
11.
12.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.CrossRefPubMed
13.
Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results from the BICC-C study. J Clin Oncol. 2008;26:689–90.CrossRefPubMed
14.
Stathopoulos GP, Batziou C, Trafalis D, et al. Treatment of colorectal cancer with and without bevacizumab: A phase III study. Oncology. 2010;78:376–81.CrossRefPubMed
15.
Passardi A, Nanni O, Tassinari D, et al. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: Final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol. 2015;26:1201–7.CrossRefPubMed
16.
Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol. 2008;26:2013–9.CrossRefPubMed
17.
Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–44.CrossRefPubMed
18.
Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol. 2005;23:3697–705.CrossRefPubMed
19.
Botrel TE, Clark LG, Paladini L, et al. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: A systematic review and meta-analysis. BMC Cancer. 2016;16:677.CrossRefPubMedPubMedCentral
20.
21.
Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomized phase 3 trial. Lancet Oncol. 2013;14:29–37.CrossRefPubMed
22.
Masi G, Salvatore L, Boni L, et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEPYP trial. Ann Oncol. 2015;26:724–30.CrossRefPubMed
23.
Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499–506.CrossRefPubMed
24.
Chau I, Joulain F, Iqbal SU, et al. A VELOUR post hoc subset analysis: Prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. BMC Cancer. 2014;14:605.CrossRefPubMedPubMedCentral
25.
Folprecht G, Pericay C, Saunders MO, et al. Oxaliplatin and 5‑FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: The AFFIRM study. Ann Oncol. 2016;27:1273–9.CrossRefPubMed
26.
Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomized, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16:499–508.CrossRefPubMed
27.
Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomized, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–12.CrossRefPubMed
28.
Lambrechts D, Lenz HJ, de Haas S, et al. Markers for response for the Antiangiogenic Agent Bevacizumab. J Clin Oncol. 2013;31:1219–30.CrossRefPubMed
29.
Dienstmann R, Vermeulen L, Guinney J, et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:79–92.CrossRefPubMed
Metadaten
Titel
Antiangiogenic therapies in colorectal cancer
verfasst von
Elisabeth Stragier
Hans Prenen, MD, PhD
Publikationsdatum
25.10.2017
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0359-8

Weitere Artikel der Ausgabe 4/2017

Update on squamous cell carcinoma of the head and neck

  • Open Access
  • short review

Antiangiogenic therapy in breast cancer

  • Open Access
  • review

Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update

  • Open Access
  • short review

ASCO 2017—making a difference in cancer care with you

  • editorial

ASCO 2017—highlights of gynecological cancer

  • Open Access
  • short review

Aggressive lymphoma 2016: revision of the WHO classification

  • Open Access
  • short review